100 related articles for article (PubMed ID: 20941458)
21. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Kaiser B; Fareed J
Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
[TBL] [Abstract][Full Text] [Related]
22. Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.
Daykin HJ; Sturgeon SA; Jones C; Wright CE
Thromb Res; 2006; 118(6):755-62. PubMed ID: 16410020
[TBL] [Abstract][Full Text] [Related]
23. The safety of fondaparinux for the prevention and treatment of venous thromboembolism.
Turpie AG
Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449
[TBL] [Abstract][Full Text] [Related]
24. Anesthetic technique does not affect the performance of a rabbit model of arterial cyclic flow reductions: a pilot study.
Charbonneau S; Girard F; Boudreault D; Ruel M; Hardy JF
Can J Anaesth; 2007 Apr; 54(4):269-75. PubMed ID: 17400978
[TBL] [Abstract][Full Text] [Related]
25. Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications.
Fonseca RJ; Santos GR; Mourão PA
Thromb Haemost; 2009 Nov; 102(5):829-36. PubMed ID: 19888516
[TBL] [Abstract][Full Text] [Related]
26. On the use of prothrombin complex concentrate in patients with coagulopathy requiring tooth extraction.
Morimoto Y; Niwa H; Nakatani T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Dec; 110(6):e7-10. PubMed ID: 21112526
[TBL] [Abstract][Full Text] [Related]
27. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
[TBL] [Abstract][Full Text] [Related]
28. Prothrombin complex concentrate (PCC) and its effect on reversing newer oral anticoagulants.
Kappes J
S D Med; 2012 Oct; 65(10):396-7. PubMed ID: 23098000
[No Abstract] [Full Text] [Related]
29. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
Bauer KA
Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
[TBL] [Abstract][Full Text] [Related]
30. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
31. The effects of a polymerized bovine-derived hemoglobin solution in a rabbit model of arterial thrombosis and bleeding.
Marret E; Bonnin P; Mazoyer E; Riou B; Jacobs T; Coriat P; Samama CM
Anesth Analg; 2004 Mar; 98(3):604-10, table of contents. PubMed ID: 14980905
[TBL] [Abstract][Full Text] [Related]
32. Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal.
Pabinger I; Tiede A; Kalina U; Knaub S; Germann R; Ostermann H;
Ann Hematol; 2010 Mar; 89(3):309-16. PubMed ID: 19787352
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
Ostermann H; Haertel S; Knaub S; Kalina U; Jung K; Pabinger I
Thromb Haemost; 2007 Oct; 98(4):790-7. PubMed ID: 17938803
[TBL] [Abstract][Full Text] [Related]
34. Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage.
Herzog E; Kaspereit F; Krege W; Doerr B; Mueller-Cohrs J; Pragst I; Morishima Y; Dickneite G
Anesthesiology; 2015 Feb; 122(2):387-98. PubMed ID: 25419685
[TBL] [Abstract][Full Text] [Related]
35. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
[TBL] [Abstract][Full Text] [Related]
36. [Direct and indirect effects of epoietin alpha in an experimental model of thrombosis and bleeding in the rabbit].
Pham Tourreau S; Fattorutto M; Bonnin P; Mazoyer E; Raphaël M; Morin F; Cupa M; Samama CM
Ann Fr Anesth Reanim; 2003 Dec; 22(10):870-8. PubMed ID: 14644369
[TBL] [Abstract][Full Text] [Related]
37. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis.
Folts J
Circulation; 1991 Jun; 83(6 Suppl):IV3-14. PubMed ID: 2040070
[TBL] [Abstract][Full Text] [Related]
38. Fondaparinux or enoxaparin: a comparative study of postoperative bleeding in coronary artery bypass grafting surgery.
Landenhed M; Johansson M; Erlinge D; Olsson ML; Bjursten H
Scand Cardiovasc J; 2010 Apr; 44(2):100-6. PubMed ID: 19961287
[TBL] [Abstract][Full Text] [Related]
39. [A study of human annexin V derivative: its effects of anticoagulation and antithrombosis].
Ju CW; Wang LS; Yang X; Ma GS; Hua ZC; Gao XY
Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):540-3. PubMed ID: 15569533
[TBL] [Abstract][Full Text] [Related]
40. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
Himber J; Kirchhofer D; Riederer M; Tschopp TB; Steiner B; Roux SP
Thromb Haemost; 1997 Sep; 78(3):1142-9. PubMed ID: 9308768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
